This included 363 patients with unresectable or metastatic colorectal cancer and compared the combination of MEK inhibitor and PD-L1 inhibitor against PD-L1 inhibitor alone or regorafenib (EGFR/VEGF inhibitor). This evidence concerns the gene CD274 and metastatic colorectal cancer.